Iris Robinson has shown ‘remarkable courage and tenacity' in cancer fight
Peter Robinson has praised the 'remarkable courage and tenacity' of his wife Iris as she battles cancer.
The former DUP leader and first minister said an event to unveil his portrait at Stormont's Parliament Buildings had been delayed for some time due to the 'unpredictable ups and downs' of his wife's illness.
Mr Robinson retired from politics in 2016.
His wife Iris Robinson is also a former DUP MP and MLA, but has stayed out of public life since it emerged in 2010 that she had had an affair and gave developers' money to her teenage lover.
Mr Robinson told a ceremony in the Great Hall at Stormont that it had been 'some considerable time since I retired'.
He added: 'It is in no sense any tardiness on the part of the Speaker's Office, the commission or the Assembly staff that it has taken seven or eight years for this event to occur.
'Some of you will know that for the past few years my wife Iris has had cancer, she has been operated and battling through it.
'But it still provides unpredictable ups and downs.'
Speaking to the media afterwards, Mr Robinson said his wife had gone through an operation and there had been complications.
He said: 'I don't want to go into the health issues but she has a remarkable courage and tenacity.
'She is going through the ups and downs. One say she is in perfect form and the next day she is having to deal with issues.
'So it is with all who have gone through that difficult experience.
'Probably it brings me out with a lot more respect for those who are involved in our health services.
'We really do have some tremendous people working in our hospitals and elsewhere in our health service.
'They don't get the credit that they deserve.
'Maybe a bit more of the funding should go to them rather than those who are administrators of the process.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
World's most deadly diseases will be kept at new Surrey lab
The world's most dangerous diseases will be researched at state-of-the-art laboratories in Surrey. The brand new National Biosecurity Centre in Weybridge will aim to prevent future pandemics by keeping various incurable and fatal viruses in its facilities. It will be handed the highest classification of lab biosecurity, allowing researchers to study the deadliest diseases, known as biosafety level four pathogens, which include Ebola. This upgrade in rating gives it the same classification as the UK Healthy Security Agency base at Porton Down. But operations in Weybridge will take on a much wider scope, with the facility set to analyse a range of infected farm animals, not just rodents. The facility will also help prepare for the possibility of a terror attack involving biological weapons. Staff at the site will do their research in special self-contained suits with their own air supply, air locks, negative air pressure and disinfection showers, allowing them to safely handle the dangerous viruses. They will also analyse currently unknown diseases including Disease X, a hypothetical pathogen that will lead to the next pandemic. On Monday, the Department for Environment, Food & Rural Affairs announced it would fund the labs with £1billion of taxpayer money, part of a larger £2.8bn revamp of the Government's premier animal disease centre. It comes after warnings from the National Audit Office that the Government was not properly prepared for a major outbreak of animal disease. Such diseases include bird flu, bluetongue and African swine fever and can pose serious threats to England's farming sector, food security, and wildlife, and are a major and increasing risk to public health. About 60 per cent of all known human infectious diseases can be transmitted from animals to people, and three quarters of emerging infectious diseases originate in animals, officials warned. The 'record' investment will complete the redevelopment of the crumbling animal science facilities at Weybridge, which the National Audit Office (NAO) recently warned was at 'very high' risk of site failure. Environment Secretary Steve Reed said: 'The first role of any Government is national security. 'That is why we are making a record investment into the nation's biosecurity capabilities and, in turn, our national security, after years of chronic underfunding. 'Farmers and food producers will now be better protected from diseases, our food security strengthened, and public health better safeguarded against future pandemics.' Jenny Stewart, senior science director at the Animal and Plant Health Agency, which runs the labs, said the funding was a 'vital milestone' in the delivery of the new facilities. 'Our scientists and specialists at Weybridge are at the heart of the UK's disease surveillance and response capability and provide a global centre of expertise,' she added. 'Investment on this scale will enable them to continue their critical work in modern, fit-for-purpose facilities, supported by the very latest technologies.' The Government said work was already under way at the Weybridge site, with the first interim labs to support science ready in 2027 and 2028, and the national biosecurity centre due to be operational in 2033-34.
The Guardian
2 hours ago
- The Guardian
CDC vaccine report cites study that does not exist, says scientist listed as author
A review on the use of the preservative thimerosal in vaccines slated to be presented on Thursday to the US Centers for Disease Control and Prevention's (CDC) outside vaccine committee cites a study that does not exist, the scientist listed as the study's author said. The report, called Thimerosal as a Vaccine Preservative published on the CDC website on Tuesday, is to be presented by Lyn Redwood, a former leader of the anti-vaccine group Children's Health Defense. It makes reference to a study called Low-level neonatal thimerosal exposure: Long-term consequences in the brain, published in the journal Neurotoxicology in 2008, and co-authored by UC Davis professor emeritus Robert Berman. But according to Berman, 'it's not making reference to a study I published or carried out.' Berman said he co-authored a similarly named study in a different journal – Toxicological Sciences – that came to different conclusions than those suggested by Redwood. 'We did not examine the effects of thimerosal in microglia … I do not endorse this misrepresentation of the research,' he said. Reuters is the first to report on the inaccurate citation from Redwood's planned presentation. The meeting has become increasingly controversial after the US health secretary Robert F Kennedy Jr, just weeks ago abruptly fired all previous 17 members of the expert panel and named eight new members, half of whom have advocated against vaccines. Kennedy, a long-time anti-vaccine activist, founded the Children's Health Defense. Both Republican senator Bill Cassidy of Louisiana and Democratic senator Patty Murray of Washington state said the meeting on 25 and 26 June should be postponed. The summary of the presentation suggested that there are enough thimerosal-free flu vaccines and that all pregnant women, infants and children should receive only those shots. It was not clear if the new advisory panel would be asked to vote on such a move. Redwood's presentation was in contrast to a separate report posted by CDC staff on the CDC website on Tuesday that says evidence does not support a link between thimerosal-containing vaccines and autism or other neurodevelopmental disorders. Kennedy has long pushed a link between vaccines and autism contrary to scientific evidence. Redwood could not be immediately reached for comment. An HHS spokesperson said the study being referenced was the Toxicological Sciences study Berman said was being misrepresented. The CDC's briefing material reviewed some studies on neurodevelopmental outcomes and vaccines that contain thimerosal, which has long been used in the US in multi-dose vials of medicines and vaccines to prevent germs from growing in them. According to the CDC report, 96% of all influenza vaccines in the US were thimerosal free during the 2024-25 flu season. It also added that the number of pregnant women receiving a thimerosal-containing flu vaccine has decreased over time, with only 0.3% of doses given in 2024 containing thimerosal. Kennedy wrote a book in 2014 claiming that thimerosal, a mercury-based preservative, causes brain damage. On Monday, Cassidy, who heads the US Senate committee on health, education, labor and pensions, called for the meeting to be delayed, saying it should not take place with a relatively small panel and without a CDC director in place. Murray, a senior member and former chair of the Help Committee, has also called for the fired panel members to be reinstated or the meeting be delayed until new members are appropriately vetted.
The Independent
3 hours ago
- The Independent
Mother's delight as gene therapy offers hope to three-year-old
A child with a life-threatening disease has become the youngest in the UK to receive a groundbreaking gene therapy. Three-year-old Gunreet Kaur has a rare inherited condition that affects children's physical, mental and behavioural development. Children with aromatic l-amino acid decarboxylase (AADC) deficiency find it difficult to control their head, blood pressure and heart rate. But after receiving the new gene therapy, called Upstaza, Gunreet has made progress that her mother thought would never be possible, such as new movements and vocalising. It is hoped that she will make further strides as she ages. Gunreet, from Hayes in west London, was nine months old when she was diagnosed with the condition. She received the treatment in February 2024 at the world-renowned Great Ormond Street children's hospital (GOSH), which is the only hospital in the UK offering the treatment to children. Sandeep Kaur said Gunreet has made 'great progress' since her treatment. 'When Gunreet was about seven months old I noticed she wasn't reaching her milestones at the same age that her older brother did,' she said. 'She couldn't hold her own head up or reach out for items. She cried a lot and always wanted to be held. 'Since having the gene therapy, Gunreet has made great progress. 'She cries less, smiles more, and can reach for objects. 'She can hold her head up and is trying to sit up, she's recently learned how to roll from her stomach to her back which is fantastic to see. 'It means a lot to me that Gunreet was able to have this gene therapy – her general health has improved, she has more co-ordination, she can bring her palms together and is able to move her hand to her mouth.' AADC deficiency is caused by a mutation in the gene that produces the AADC enzyme, this enzyme is needed to produce a neurotransmitter called dopamine which is important in controlling movement. People with AADC deficiency do not have a working version of the enzyme, which means that they have little or no dopamine in the brain. This means that they can suffer developmental delays, weak muscle tone and inability to control the movement of the limbs. It can also lead to painful episodes for affected children. The condition is rare and often deadly, with many children with AADC deficiency not reaching adulthood. The medicine, also known as eladocagene exuparvovec, consists of a virus that contains a working version of the AADC gene. The treatment is delivered by millimetre precision to an exact location in the brain of the patient by a team of medics assisted by a robotic surgery tool. When given to the patient, it is expected that the virus will carry the AADC gene into nerve cells, enabling them to produce the missing enzyme. This is expected to enable the cells to produce the dopamine they need to work properly, which will improve symptoms of the condition. It is the first NHS England commissioned gene therapy in the UK infused directly into the brain. Professor Manju Kurian, consultant paediatric neurologist at GOSH, said 'AADC deficiency is a rare condition but often a cruel one that has such a profound impact on children and their carers and families. 'We know children with the condition have painful episodes that can last for hours and, as their condition progresses, their life becomes more and more difficult. 'It's incredible to me that I can now prescribe novel gene therapies just as I would prescribe paracetamol and antibiotics. 'While the treatment is now available under the NHS at GOSH, we can only do this by working collaboratively across teams inside and outside the hospital, from physios and surgeons to dietitians and speech therapists, alongside partnerships with companies who supply these therapies. 'It's great to see how this treatment has been able to help babies and children across the country like Gunreet. 'The natural history of the condition is that most patients cannot fully hold their head or make any developmental progress after that milestone. 'Gunreet's progress over the last year has been really impressive in that context, as well as the virtual disappearance of the eye crises. 'We're hopeful that one day she will be able to talk or walk, as seen in some of the young patients treated in the clinical trial.' Professor James Palmer, NHS medical director for specialised commissioning, said: 'This is wonderful news for Gunreet and her family, and a powerful example of how these commitments are translating into real improvements in people's lives. 'By bringing cutting-edge medicines like eladocagene exuparvovec into the health service and setting up our expert clinical teams to successfully deliver them, the NHS is making clear its commitment to improving care through innovation.'
